Currently, there are 59.92M common shares owned by the public and among those 53.41M shares have been available to trade.
The company’s stock has a 5-day price change of -5.14% and -27.14% over the past three months. PLRX shares are trading -40.86% year to date (YTD), with the 12-month market performance down to -51.89% lower. It has a 12-month low price of $10.60 and touched a high of $22.52 over the same period. PLRX has an average intraday trading volume of 436.17K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -13.74%, -17.90%, and -29.40% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Pliant Therapeutics Inc (NASDAQ: PLRX) shares accounts for 99.75% of the company’s 59.92M shares outstanding.
It has a market capitalization of $646.13M and a beta (3y monthly) value of 1.17. The earnings-per-share (ttm) stands at -$2.86. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.50% over the week and 6.13% over the month.
Earnings per share for the fiscal year are expected to decrease by -23.65%, and -9.70% over the next financial year.
Looking at the support for the PLRX, a number of firms have released research notes about the stock. Wells Fargo stated their Overweight rating for the stock in a research note on December 08, 2023, with the firm’s price target at $41. Canaccord Genuity coverage for the Pliant Therapeutics Inc (PLRX) stock in a research note released on May 18, 2023 offered a Buy rating with a price target of $48. Robert W. Baird was of a view on April 13, 2023 that the stock is Outperform, while Stifel gave the stock Buy rating on December 14, 2022, issuing a price target of $33. JP Morgan on their part issued Overweight rating on December 07, 2022.
